1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,750 | 7,400 | 12.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus | 1 | Benzinga.com | ||
| Do | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Do | Eupraxia meldet positive Daten aus Studie zur Behandlung von EoE | 1 | Investing.com Deutsch | ||
| Do | Eupraxia reports positive data from EoE treatment trial | 3 | Investing.com | ||
| Do | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy | 136 | GlobeNewswire (Europe) | At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1- At lower doses, patients maintained the improvements... ► Artikel lesen | |
| EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 14.11.25 | Cantor Fitzgerald reiterates Overweight rating on Eupraxia stock at $11 | 1 | Investing.com | ||
| 14.11.25 | Eupraxia: Cantor Fitzgerald bestätigt "Overweight"-Rating und sieht 73 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 13.11.25 | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI | 196 | GlobeNewswire (Europe) | The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus... ► Artikel lesen | |
| 13.11.25 | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.11.25 | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals ends Q3 with cash of $89M | 1 | Stockwatch | ||
| 04.11.25 | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results | 67 | GlobeNewswire (Europe) | Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by... ► Artikel lesen | |
| 04.11.25 | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.10.25 | This analyst loves Eupraxia Pharmaceuticals | 1 | Cantech Letter | ||
| 02.10.25 | H.C. Wainwright bestätigt Kaufempfehlung für Eupraxia nach starken Studiendaten | 1 | Investing.com Deutsch | ||
| 02.10.25 | H.C. Wainwright reiterates Buy rating on Eupraxia Pharmaceuticals stock | 1 | Investing.com | ||
| 30.09.25 | Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study | 1 | Benzinga.com | ||
| 30.09.25 | Eupraxia Pharmaceuticals stock maintains Overweight rating at Cantor Fitzgerald | 3 | Investing.com | ||
| 29.09.25 | Eupraxia reports positive data from highest dose cohort in EoE trial | 1 | Investing.com | ||
| 29.09.25 | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs | 511 | GlobeNewswire (Europe) | Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients... ► Artikel lesen | |
| 29.09.25 | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 4 | SEC Filings |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,350 | +2,27 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,710 | -1,01 % | PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases | MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration... ► Artikel lesen | |
| EXACT SCIENCES | 87,43 | -0,25 % | MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences | MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences IRVINE, CA - January 12, 2026 (GlobeNewswire) -... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,826 | -0,98 % | Arbutus Biopharma Corporation: Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech... ► Artikel lesen | |
| XOMA ROYALTY | 22,800 | -0,87 % | XOMA Royalty Corporation: XOMA Royalty Announces CFO Transition | EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,410 | -2,03 % | Zukunft der Krebstherapie: Warum diese NASDAQ-Aktie jetzt im Januar eine außergewöhnliche Einstiegschance bietet | ||
| IMMUNIC | 0,553 | -3,15 % | EQS-News: Immunic AG: Immunic Highlights 2025 Accomplishments and Upcoming Milestones | Issuer: Immunic AG
/ Key word(s): Miscellaneous/Conference
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
07.01.2026 / 12:30 CET/CEST
The issuer is... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,059 | +0,27 % | IOVANCE BIOTHERAPEUTICS, INC. - 8-K, Current Report | ||
| GUARDANT HEALTH | 91,32 | -1,00 % | Guardant Health, Inc. - 8-K, Current Report | ||
| COHERUS ONCOLOGY | 1,363 | -3,95 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen | |
| CURIS | 0,775 | 0,00 % | Curis closes private placement for up to $80.8 million in funding | ||
| CYTOKINETICS | 55,00 | -0,90 % | Jefferies raises Cytokinetics stock price target to $90 on ACACIA study | ||
| FATE THERAPEUTICS | 0,901 | -2,19 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate... ► Artikel lesen | |
| AGENUS | 3,660 | +0,55 % | Agenus Inc.: France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas | Updated national AAC protocol supports hospital-based, fully-reimbursed compassionate access across three solid tumor settings Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,167 | +2,76 % | Rocket Pharma cut at J.P. Morgan on risks to Danon disease program |
EUPRAXIA PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,400 (-5,67 %) liegt der Kurs bei 6,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EUPRAXIA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.